The supplementation with omega-3 fatty acids has no benefit in treating multiple sclerosis, according to a clinical trial that appeared in the JAMA's Archives of Neurology. However, researchers acknowledged the randomized controlled trial was underpowered.
The supplementation with omega-3 fatty acids has no benefit in treating multiple sclerosis (MS), according to a clinical trial that appeared in the JAMA’sArchives of Neurology. However, researchers acknowledged the randomized controlled trial was underpowered.
The study investigated the effects of omega-3 fatty acid supplementation as a single therapy or in combination with interferon beta-1a, a drug used in the treatment of MS, on the effects of disease activity.
Researchers assessed 92 patients with MS in the double-blind, placebo-controlled trial, using magnetic resonance imaging to measure disease activity by the number of new lesions in the brain.
There was no difference between the 2 groups in the number of relapses or lesions during the first 6 months of treatment or after 24 months, researchers said. In addition, no differences were detected either in fatigue or quality-of-life scores.
Researchers noted that their results were in contrast with 2 other studies reporting a possible positive effect.
The authors commented that their data does not suggest omega-3 fatty acid supplementation is harmful, or that such supplementation interfered with interferon beta treatment, which they noted can reduce disease activity in the relapsing-remitting course of MS.
Psychiatric Pharmacist Working to Optimize Treatment, Improve Patient Safety
December 13th 2024A conversation with Nina Vadiei, PharmD, BCPP, clinical associate professor in the Division of Pharmacotherapy at University of Texas at Austin College of Pharmacy and a clinical pharmacy specialist in psychiatry at the San Antonio State Hospital.